Offset contracts to help provide over 80 per cent of cancer patients in Moscow with Russian-made medicines
(9).jpg)
Offset contracts implemented after the site reaches the target operational parameters will help Moscow provide 80 per cent of its cancer and blood cancer patients with good-quality, high-efficiency Russian-made medicines. It was announced by Anastasia Rakova, Deputy Moscow Mayor for Social Development.
“Recently, the Moscow Government made the decision to hold another digital bidding procedure for a new offset contract for medical drug supplies, including medicines used in oncology and oncohematology. Sergei Sobyanin has signed the appropriate resolution. Contracts like that are extremely important and beneficial both for the city and the producers. Their advantages are obvious: the city authorities guarantee stable purchases of drugs for Moscow healthcare institutions, the city gets a new high-tech production site that will help cut dependence on imported products and create new jobs for Muscovites. After the new site reaches its full capacity, for instance, offset contracts will within a few years enable us to provide over 80 per cent of cancer and blood cancer patients with modern, Russian-made medicines,” said Ms. Rakova.
The Moscow Government has already signed five offset contracts worth RUB 72.7 billion in total. Four of them are for drugs and medical device production and another one is for baby food production. Three of those production sites are already operational and supplying products to the city.
“Moscow has approved 11 bidding procedures for offset contracts this year. Five of them are for the pharma industry. The winners have to invest at least RUB 5.5 billion in localizing production of over 80 generic types of vital drugs,” announced Vladimir Yefimov, Deputy Moscow Mayor for Economic Policy and Property and Land Relations.
Moscow is the first Russian region to implement the new federal clinical guidelines for the most common cancer types treatment. The city has reached that milestone three years ahead of schedule.